Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
Frank L. van de Veerdonk, Ilse J.E. Kouijzer, Aline de Nooijer, Hans G. van der Hoeven, Coen Maas, Mihai G. Netea, Roger J. M. Brüggemann
Abstract
matched controls, only 3 (17%) showed a spontaneous reduction in oxygen supplementation of 3 L/min or greater within 24 hours. We noted that in 3 patients treated with icatibant there was a resurgence in the need for oxygen supplementation. Icatibant treatment was well tolerated in all 10 patients who received the drug. There were no severe adverse events. There was no clear association with D-dimer concentrations and fever.
Topics & Concepts
IcatibantCoronavirus disease 2019 (COVID-19)KininAntagonistMedicineReceptor antagonist2019-20 coronavirus outbreakBradykininSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineReceiptReceptorPharmacologyVirologyDiseaseInfectious disease (medical specialty)Computer scienceWorld Wide WebOutbreakCoagulation, Bradykinin, Polyphosphates, and AngioedemaCOVID-19 Clinical Research StudiesComplement system in diseases